
GSH¿Í °áÇÕµÈ NefazodoneÀÇ MetaboliteµéÀ» ÃʰíÁ¤È® MS/MSn µ¥ÀÌÅÍ¿Í MetWorks ¼ÒÇÁÆ®¿þ¾î¸¦ ÀÌ¿ëÇÏ¿© ´©±¸³ª ¼Õ½±°Ô °á°ú¸¦ È®ÀÎÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» Á¦½ÃÇÑ´Ù.

1. |
LTQ OrbitrapÀº ÃʰíÁ¤È®µµ/ÃʰíºÐÇØ´ÉÀÇ Áú·®ºÐ¼®±â·Î¼ ±âÁ¸ÀÇ FT MS¿¡ ºñÇØ »ç¿ë¹æ¹ýÀÌ ½±°í, À¯Áöº¸¼ö°¡ °£ÆíÇÑ ¹Ý¸é FT MS¿Í °ÅÀÇ À¯»çÇÑ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Ù. »Ó¸¸ ¾Æ´Ï¶ó ÀÌ¹Ì ±¹³»¿Ü ¸¹Àº ¿¬±¸Àڵ鿡°Ô ±× ¼º´ÉÀ» ÀÔÁõ¹Þ°í ÀÖ´Â Â÷¼¼´ë Áú·®ºÐ¼®±âÀÌ´Ù. ±×¸®°í ¹«¾ùº¸´Ù LTQ OrbitrapÀº ¹ÌÁö½Ã·á(Unknown Compounds)¿¡ ´ëÇÑ ¿ø¼Ò ¼ººÐ(Elemental Composition)À» °áÁ¤Áþ´Âµ¥ ±× Ź¿ùÇÔÀ» °¡Áö°í ÀÖ´Ù. ƯÈ÷ ÃÊ°í°¨µµ¸¦ °âºñÇÑ °íÁ¤È®/°íºÐÇØ´ÉÀÇ µ¥ÀÌÅÍ´Â Full ScanÇÏ¿© ºÐÀÚ·®À» È®ÀÎÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó Untargeted Compounds¸¦ Intensity¿¡ µû¶ó data dependentÇÏ°Ô ÀÚµ¿À¸·Î MSn µ¥ÀÌÅ͸¦ ¾òÀ» ¼ö Àֱ⠶§¹®¿¡ Biotransformation°ú °°Àº º¹ÀâÇÑ È¥ÇÕ¹°ÀÇ Á¤¼º ºÐ¼®¿¡ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ Á¤º¸µéÀ» Á¦°øÇÒ ¼ö ÀÖ´Ù. |
2. |
MetWorksTM ¼ÒÇÁÆ®¿þ¾î´Â ºÐ¼®ÇϰíÀÚ ÇÏ´Â Drug°ú »ýü ³» º¯È¿¡ µû¸¥ ´Ù¾çÇÑMetaboliteµéÀ» º¸´Ù ºü¸¥ ½Ã°£ ³» ÀÚµ¿À¸·Î ã°í ºÐ¼®Çϴµ¥ µµ¿òÀ» ÁÖ´Â ¼ÒÇÁÆ®¿þ¾îÀÌ´Ù. ¾Æ¿ï·¯ MetworksTM ¼ÒÇÁÆ®¿þ¾î´Â ±¸Á¶ºÐ¼®¿ë ¼ÒÇÁÆ®¿þ¾îÀÎ Mass Frontier¸¦ ÇÔ²² ±¸µ¿ÇÒ ¼ö ÀÖ¾î¼ ÀÌ¹Ì Ã£Àº MetaboliteµéÀÇ ±¸Á¶¸¦ È®ÀÎÇϴµ¥ ¸Å¿ì À¯¿ëÇÏ¸ç Æí¸®ÇÏ´Ù.
º» ½ÇÇè¿¡¼´Â ƯÈ÷ MetWorksTM ¼ÒÇÁÆ®¿þ¾î ±â´É Áß MMDF (Multiple Mass Defect Filters)ÀÇ ±â´ÉÀ» ÀÌ¿ëÇÏ¿© Parent Drug°ú °ü°èµÈ Full Scan Spectra¸¦ High Mass Tolerance·Î FilteringÇÏ¿© Backgrounds°¡ Á¦°ÅµÈ µ¥ÀÌÅÍ¿¡¼ MetaboliteµéÀ» ãÀ» ¼ö ÀÖ¾ú´Ù. |
|